Lilly announces a new cancer deal, paying Ajax up to $2.3B for JAK inhibitor – Endpoints News
Lilly announces a new cancer deal, paying Ajax up to $2.3B for JAK inhibitor Endpoints NewsLilly to acquire Ajax…
Browsing Tag